Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Anika Therapeutics | ANIK | Sep 20, 2024 | 25.50 | +0.55 |
Anixa Biosciences | ANIX | Sep 20, 2024 | 3.48 | +1.75 |
Annaly Capital Management | NLY | Sep 20, 2024 | 20.88 | +0.38 |
Annaly Capital Management F Pref | NLY-F | Sep 20, 2024 | 25.47 | -0.35 |
Annaly Capital Management G Pref | NLY-G | Sep 20, 2024 | 25.49 | +0.67 |
Annaly Capital Management I Pref | NLY-I | Sep 20, 2024 | 25.54 | -0.23 |
Annexon | ANNX | Sep 20, 2024 | 7.03 | +0.07 |
Annovis Bio | ANVS | Sep 20, 2024 | 8.47 | -1.97 |
ANSYS | ANSS | Sep 20, 2024 | 320.25 | -0.63 |
Antelope Enterprise | AEHL | Sep 20, 2024 | 0.98 | -4.20 |
Anterix | ATEX | Sep 20, 2024 | 39.34 | -0.53 |
Antero Midstream | AM | Sep 20, 2024 | 14.81 | +1.58 |
Antero Resources | AR | Sep 20, 2024 | 27.44 | +0.70 |
Anywhere Real Estate | HOUS | Sep 20, 2024 | 5.84 | +0.69 |
Aon | AON | Sep 20, 2024 | 347.03 | +0.02 |
APA | APA | Sep 20, 2024 | 25.07 | -1.14 |
Apartment Investment and Management | AIV | Sep 20, 2024 | 9.24 | -0.54 |
Apellis Pharmaceuticals | APLS | Sep 20, 2024 | 32.51 | -11.49 |
APi Group | APG | Sep 20, 2024 | 35.22 | -1.62 |
Apogee Enterprises | APOG | Sep 20, 2024 | 67.50 | -2.92 |
Apogee Therapeutics | APGE | Sep 20, 2024 | 58.43 | +10.35 |
Apollo Commercial Real Estate Finance | ARI | Sep 20, 2024 | 9.65 | -1.63 |
Apollo Global Management | APO | Sep 20, 2024 | 124.48 | +2.35 |
Apollomics A | APLM | Sep 20, 2024 | 0.13 | -1.75 |
AppFolio A | APPF | Sep 20, 2024 | 233.79 | +0.85 |
Appian A | APPN | Sep 20, 2024 | 33.41 | -1.01 |
Apple | AAPL | Sep 20, 2024 | 228.20 | -0.29 |
Apple Hospitality REIT | APLE | Sep 20, 2024 | 15.35 | +1.12 |
Applied Digital | APLD | Sep 20, 2024 | 6.02 | +8.27 |
Applied DNA Sciences | APDN | Sep 20, 2024 | 1.25 | +2.89 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.